Rheumatoide Arthritis – das kardiovaskuläre Risiko ist hoch, aber beeinflussbar

Schlüsselwörter

rheumatoide Arthritis - Risikofaktoren - Herz-Kreislauf-Erkrankungen

Keywords

rheumatoid arthritis - risk factors - cardiovascular diseases

• Literatur

• 1 Avina-Zubieta JA, Thomas J, Sadatsafavi M et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71: 1524-1529
• 2 Banerjee S, Compton AP, Hooker RS et al. Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol 2008; 101: 1201-1205
• 3 Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003
• 4 De Vera MA, Choi H, Abrahamowicz M et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011; 70: 1020-1024
• 5 Fiehn C. Rheumatoide Arthritis – Remission im Fokus einer zielorientierte Therapie. Dtsch Med Wochenschr 2012; 137: 206-209
• 6 Fiehn C. Rheumatoide Arthritis: Meilensteine für Klassifikation und Therapie. Dtsch Med Wochenschr 2011; 136: 203-205
• 7 Kerola AM, Kauppi MJ, Kerola T et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?. Ann Rheum Dis 2012; 71: 1606-1615
• 8 Kleinert S, Krueger K. [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis]. Z Rheumatol 2011; 70: 464-472
• 9 Lindhardsen J, Ahlehoff O, Gislason GH et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-934
• 10 Maradit-Kremers H, Crowson CS, Nicola PJ et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-411
• 11 Micha R, Imamura F, Wyler von BM et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-1370
• 12 Myasoedova E, Crowson CS, Kremers HM et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1310-1314
• 13 Myasoedova E, Crowson CS, Kremers HM et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70: 482-487
• 14 Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-331
• 15 Reiss AB, Carsons SE, Anwar K et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58: 3675-3683
• 16 Semb AG, Kvien TK, DeMicco DA et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012; 64: 2836-2846
• 17 Sheng X, Murphy MJ, Macdonald TM et al. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012; 39: 32-40
• 18 Westlake SL, Colebatch AN, Baird J et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011; 50: 518-531
• 19 Westlake SL, Colebatch AN, Baird J et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49: 295-307